Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Intangibles (2023 - 2025)

Iovance Biotherapeutics has reported Intangibles over the past 3 years, most recently at $279.3 million for Q4 2025.

  • Quarterly results put Intangibles at $279.3 million for Q4 2025, down 1.09% from a year ago — trailing twelve months through Dec 2025 was $279.3 million (down 1.09% YoY), and the annual figure for FY2025 was $279.3 million, down 1.09%.
  • Intangibles for Q4 2025 was $279.3 million at Iovance Biotherapeutics, down from $335.3 million in the prior quarter.
  • Over the last five years, Intangibles for IOVA hit a ceiling of $341.4 million in Q2 2025 and a floor of $223.6 million in Q3 2023.
  • Median Intangibles over the past 3 years was $282.4 million (2024), compared with a mean of $279.6 million.
  • Biggest five-year swings in Intangibles: rose 18.03% in 2024 and later decreased 3.04% in 2025.
  • Iovance Biotherapeutics' Intangibles stood at $239.3 million in 2023, then increased by 18.03% to $282.4 million in 2024, then dropped by 1.09% to $279.3 million in 2025.
  • The last three reported values for Intangibles were $279.3 million (Q4 2025), $335.3 million (Q3 2025), and $341.4 million (Q2 2025) per Business Quant data.